Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2013

01-02-2013 | Preclinical Study

Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer

Authors: Catherine L. Forse, Yildiz E. Yilmaz, Dushanthi Pinnaduwage, Frances P. O’Malley, Anna Marie Mulligan, Shelley B. Bull, Irene L. Andrulis

Published in: Breast Cancer Research and Treatment | Issue 3/2013

Login to get access

Abstract

Lymphatic invasion (LVI) is associated with disease recurrence in axillary node-negative (ANN) breast cancer. Using gene expression profiling of 105 ANN tumors, we found that podocalyxin (PODXL) was more highly expressed in tumors with LVI (LVI+) than in those without LVI (LVI−). Differences in PODXL expression were validated using real-time polymerase chain reaction as well as by immunohistochemistry in an independent set of 652 tumors on tissue microarrays. Disease-free survival (DFS) analyses were conducted for association of high PODXL protein expression with risk of distant recurrence overall and within breast cancer subtypes using both Cox and cure-rate models. High PODXL expression was associated with poor prognosis features including large tumor size, high histological grade, estrogen and progesterone receptor negativity, and with clinical alterations characteristic of the basal-like breast cancer phenotype. Surprisingly, despite having other poor prognosis characteristics, women with high PODXL expressing tumors had better long-term DFS in multivariate analysis with traditional clinicopathologic factors including LVI and HER2 status (P = 0.001). PODXL has the potential to be a useful biomarker for identifying good prognosis patients in characteristically poor prognosis breast cancer groups and may impact treatment of women with this disease.
Literature
1.
Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S et al (2004) The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 22:86–96PubMedCrossRef
2.
Kerjaschki D, Poczewski H, Dekan G, Horvat R, Balzar E, Kraft N, Atkins RC (1986) Identification of a major sialoprotein in the glycocalyx of human visceral glomerular epithelial cells. J Clin Invest 78:1142–1149PubMedCrossRef
3.
Kershaw DB, Beck SG, Wharram BL, Wiggins JE, Goyal M, Thomas PE, Wiggins RC (1997) Molecular cloning and characterization of human podocalyxin-like protein. J Biol Chem 272:15708–15714PubMedCrossRef
4.
Sassetti C, Van Zante A, Rosen SD (2000) Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins. J Biol Chem 275:9001–9010PubMedCrossRef
5.
McNagny KM, Pettersson I, Rossi F, Flamme I, Shevchenko A, Mann M, Graf T (1997) Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. J Cell Biol 138:1395–1407PubMedCrossRef
6.
Kerosuo L, Juvonen E, Alitalo R, Gylling M, Kerjaschki D, Miettinen A (2004) Podocalyxin in human haematopoietic cells. Br J Haematol 124:809–818PubMedCrossRef
7.
Doyonnas R, Kershaw DB, Duhme C, Merkens H, Chelliah S, Graf T, McNagny KM (2001) Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 194:13–27PubMedCrossRef
8.
Takeda T, Go WY, Orlando RA, Farquhar MG (2000) Expression of podocalyxin inhibits cell–cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells. Mol Biol Cell 11:3219–3232PubMed
9.
Kerjaschki D, Vernillo AT, Farquhar MG (1985) Reduced sialyation of podocalyxin–the major sialoprotein of the rat kidney glomerulus–in aminonucleoside nephrosis. Am J Path 118:343–349PubMed
10.
Pericacho M, Alonso-Martin S, Larrucea S, González-Manchón C, Fernández D, Sanchez I, Ayuso MS, Parrilla R (2011) Diminished thrombogenic responses by deletion of the podocalyxin gene in mouse megakaryocytes. PLoS One 6:e26025PubMedCrossRef
11.
Alonso-Martin S, Nowakowski A, Larrucea S, Fernández D, Vilar-Egla M, Ayuso MS, Parrilla R (2010) Overexpression of podocalyxin in megakaryocytes and platelets decreases the bleeding time and enhances the agonist-induced aggregation of platelets. Thromb Res 125:e300–e305PubMedCrossRef
12.
Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, Uhlén M, Jirström K (2011) Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 105:666–672PubMedCrossRef
13.
Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, Roskelley CD (2004) Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 64:5068–5073PubMedCrossRef
14.
Dallas MR, Chen SH, Streppel MM, Sharma S, Miatra A, Konstantopoulos K (2012) Sialofucosylated podocalyxin is a functional E- and L-selectin ligand expressed by metastatic pancreatic cancer cells. Am J Physiol 303:C616–C624CrossRef
15.
Yasuoka H, Tsujimoto M, Inagaki M, Kodama R, Tsuji H, Iwahashi Y, Mabuchi Y, Ino K, Sanke T, Nakamura Y (2012) Clinicopathological significance of podocalyxin and phosphorylated ezrin in uterine endometroid adenocarcinoma. J Clin Pathol 65:399–402PubMedCrossRef
16.
Kelley TW, Huntsman D, McNagny KM, Roskelley CD, Hsi ED (2005) Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol 124:134–142PubMedCrossRef
17.
Heukamp LC, Fischer HP, Schirmacher P, Chen X, Breuhahn K, Nicolay C, Buttner R, Gutgemann I (2006) Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions. Histopathology 49:242–247PubMedCrossRef
18.
Naishiro Y, Yamada T, Idogawa M, Honda K, Takada M, Kondo T, Imai K, Hirohashi S (2005) Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic beta-catenin protein. Oncogene 24:3141–3153PubMedCrossRef
19.
Barton Furness SG, McNagny K (2006) Beyond mere markers: functions for CD34 family of sialomucins in hematopoiesis. Immunol Res 34:13–32CrossRef
20.
Larrucea S, Butta N, Arias-Salgado EG, Alonso-Martin S, Ayuso MS, Parrilla R (2008) Expression of podocalyxin enhances the adherence, migration, and intercellular communication of cells. Exp Cell Res 314:2004–2015PubMedCrossRef
21.
Sizemore S, Cicek M, Sizemore N, Ng KP, Casey G (2007) Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 67:6183–6191PubMedCrossRef
22.
Sy JP, Taylor JM (2000) Estimation in a Cox proportional hazards cure model. Biometrics 56:227–236PubMedCrossRef
23.
Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A et al (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16:1340–1349PubMed
24.
Mulligan AM, Pinnaduwage D, Bull SB, O’Malley FP, Andrulis IL (2008) Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. Clin Cancer Res 14:4168–4174PubMedCrossRef
25.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387–391PubMedCrossRef
26.
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed
27.
Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K, Gilks CB, van de Rijn M (2002) Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 161:1557–1565PubMedCrossRef
28.
Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London
29.
Farewell VT (1982) The use of mixture models for the analysis of survival data with long-term survivors. Biometrics 38:1041–1046PubMedCrossRef
30.
Heinze G, Ploner M (2002) SAS and SPLUS programs to perform Cox regression without convergence problems. Comput Methods Programs Biomed 67:217–223PubMedCrossRef
31.
Nielsen JS, McNagny KM (2009) The role of podocalyxin in health and disease. J Am Soc Nephrol 20:1669–1676PubMedCrossRef
32.
Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed
33.
Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh LD, To TV, Zho Q, Love RR, Allred DC (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17:1545–1554PubMedCrossRef
34.
O’ Malley FP, Parkes R, Latta E, Tjan S, Zadro T, Mueller R, Arneson N, Blackstein M, Andrulis I (2001) Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 115:504–511CrossRef
Metadata
Title
Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer
Authors
Catherine L. Forse
Yildiz E. Yilmaz
Dushanthi Pinnaduwage
Frances P. O’Malley
Anna Marie Mulligan
Shelley B. Bull
Irene L. Andrulis
Publication date
01-02-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2392-y

Other articles of this Issue 3/2013

Breast Cancer Research and Treatment 3/2013 Go to the issue

Preclinical Study

2-Hydroxycinnamaldehyde inhibits the epithelial-mesenchymal transition in breast cancer cells

Preclinical study

Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer

Clinical Trial

Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis

Clinical Trial

Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes

Preclinical study

14-3-3ζ as a predictor of early time to recurrence and distant metastasis in hormone receptor-positive and -negative breast cancers

Epidemiology

Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits